Most of healthcare’s defining companies are already alive. They exist as a result that holds, a mechanism that works in a dish, a clinician’s pattern noticed across a hundred patients. At that moment they do not look like companies. They look like noise, pre-revenue, pre-team, pre-clarity, entangled in intellectual property and regulation.
This is, in our view, the single most inefficient market in venture capital: the boundary between the university laboratory and the first priced round. It is inefficient for structural reasons. The largest and best healthcare funds are designed to engage once the science is de-risked and the round is large enough to move their fund. The earliest capital, meanwhile, is often generalist, happy to write a small check, but unable to judge a mechanism or help design a regulatory path.
Edge at pre-seed comes from being early and literate in the same place at the same time.
That gap is where Sonnerie was built to operate. We believe the highest-leverage dollar in healthcare is the first institutional dollar, the one that turns a finding into a company. It is the dollar that buys the most ownership for the least capital, and the dollar whose accompanying help most changes the trajectory of the team.
Why “highest-leverage” is literal, not rhetorical
Leverage at pre-seed shows up in three ways. First, ownership: entry prices are lowest before traction exists, so conviction is rewarded with meaningful ownership in the companies that work. Second, influence: the decisions made in the first twelve months, how the company is incorporated, who joins as founding team, which regulatory pathway it targets, are the decisions that compound. Third, selection: being early and scientifically literate lets you see opportunities before they are broadly shopped, which is the only durable source of proprietary deal flow.
None of this works without the literacy to tell signal from noise. A first check written on a thesis you cannot evaluate is not conviction; it is hope. So our edge and our discipline are the same thing: we invest where our operators have built, exited, and navigated regulation, and we decline where we cannot add that judgment.
Hearing it first is a practice, not a posture
To hear the earliest signal, you have to be where it originates. For us that means university laboratories, technology transfer offices, clinician networks, and the Columbia ecosystem we came from. It means reading the science, not just the deck. And it means being willing to write the first check on incomplete information, backing the founder and the mechanism before the signal is obvious to everyone else.
That is the whole job: detect the faint, early signal of a breakthrough, and amplify it, with capital, a board seat, and the operating help to carry a finding from the bench to a fundable company. From signal to scale.